A phase I, randomized trial by Fowler et al. [23] included placebo (n = 8), low-dose intravenous vitamin C (50 mg/kg; n = 8), and high-dose vitamin C (200 mg/kg; n = 8); vitamin C reduced the levels of inflammatory markers, including C-reactive protein (CRP) and procalcitonin, in a dose-dependent manner in severe sepsis and septic shock. This evidence concerns the gene CRP and Sepsis.